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ABSTRACT
Targeted therapies specific to the BRAF-MEK-ERK signaling pathway have shown great promise in the treatment of malignant
melanoma in the last few years, with these drugs now commonly used in clinic. Melanoma cells treated using these agents
are known to exhibit increased levels of melanin pigment and tyrosinase activity. In this study we assessed the potential of
non-invasive imaging approaches (photoacoustic imaging (PAI) and magnetic resonance imaging (MRI)) to detect melanin
induction in SKMEL28 human melanoma cells, following inhibition of Hsp90 and BRAF signaling using 17-AAG and vemurafenib,
respectively. We confirmed, using western blot and spectrophotometry, that Hsp90 or BRAF inhibitor-induced melanoma cell
differentiation resulted in an upregulation of tyrosinase and melanin expression levels, in comparison to control cells. This
post-treatment increase in cellular pigmentation induced a significant increase in PAI signals that are spectrally identifiable
and shortening of the MRI relaxation times T1 and T2*. This proof-of-concept study demonstrates the potential of MRI and PAI
for detecting the downstream cellular changes induced by Hsp90 and BRAF-MEK-targeted therapies in melanoma cells with
potential significance for in vivo imaging.
Introduction
Malignant melanoma is an aggressive form of skin cancer that has shown an increased rate of incidence especially amongst the
Caucasian population over the past few years1. The discovery of the prevalence of BRAF mutation in this disease (≈50% of
cases) and the role of the oncoprotein, particularly the highly active V600E variant, in the onset and progression of melanoma2, 3
have fuelled much interest in targeting the BRAF-MEK-ERK pathway for melanoma treatment. Indeed, several inhibitors
of BRAF and MEK are now approved for the treatment of BRAF-driven melanoma (e.g. the BRAF inhibitors vemurafenib,
dabrafenib and the MEK inhibitor trametinib)4–6 and many more are in development for use either as single agents or in
combination with other anti-cancer drugs7.
Another approach for the downregulation of BRAF activity is direct degradation of the protein through inhibition of heat
shock protein 90 (Hsp90). Hsp90 is a molecular chaperone involved in maintaining the conformational stability of many
oncogenic clients including BRAF, CRAF, AKT and HER28–10. Inhibition of Hsp90 with agents such as 17-allylamino-17-
demethoxygeldanamycin (17-AAG) and AUY922 results in proteasomal degradation of the client proteins and consequently
simultaneous blockade of multiple key oncogenic signal transduction pathways, including the BRAF-MEK-ERK1/2 and PI3K-
AKT, which then leads to inhibition of proliferation, invasion, angiogenesis and induction of tumour cell redifferentiation8–13.
Hsp90 inhibitors have shown activity in several pre-clinical models of melanoma and are currently undergoing clinical testing
in several tumour types including malignant melanoma14–16.
Detecting pharmacodynamic (PD) biomarkers of the action of BRAF-MEK-ERK and Hsp90 inhibitors is key for monitoring
target blockade and modulation of downstream cellular processes in addition to probing therapeutic efficacy17–19. In this regard,
non-invasive imaging biomarkers of the downstream consequences of target modulation are highly desirable as they remove the
need for surgical intervention and afford the possibility of performing longitudinal studies in the same patient20. In particular,
molecular and functional imaging biomarkers that can inform on therapeutic activity prior to any measurable changes in tumour
size are extremely valuable. Furthermore, a non-invasive early indication of whether the treatment has “hit the target” (i.e., in
addition to measures of whether the tumour is responding) would allow more effective patient management than is currently
possible.
In this study we used photoacoustic imaging (PAI) and magnetic resonance imaging (MRI) to assess the PD biomarkers of the
downstream cellular changes that follow the inhibition of Hsp90 and BRAF signaling in melanoma cells. PAI enables the display
of optical absorption contrast with a high (sub-mm) resolution at depths of up to a few centimetres21. Multiwavelength PAI can
provide information on tissue composition by identifying spectral signatures of a wide range of endogenous chromophores,
such as melanin22, lipids23, 24 , collagen25 , myoglobin26, oxygenated and deoxygenated haemoglobin27. MRI allows the
non-invasive probing of tumour physiology providing structural as well as functional information including cellular density
and tissue relaxation parameters such as T1,T2 and T2*, which are sensitive to changes in paramagnetic molecular species
content28. These measurements are relevant in understanding water molecular dynamics in biologic systems, as they depend on
tissue microstructure and the chemical and physical environments of water protons in it29. Paramagnetic species (free metals
and radicals), such as those scavenged by melanin alter tissue local magnetic environment, producing local magnetic fields,
shortening the original relaxation parameters30. Previous work has shown that forced expression of tyrosinase in human breast
cancer cells in vitro results in increased melanin content, increased photoacoustic (PA) signals at 532 nm31 and 650 nm32, and a
reduction in T131, 32 and T231 MRI relaxation times upon exogenous administration of iron.
In this study, we posited that Hsp90 or BRAF inhibitor-induced melanoma cell differentiation will result in increased
cellular melanin levels through upregulation of tyrosinase expression and that this in turn should lead to a) increased optical
absorption detectable by PAI and b) a reduction in T1, T2 and T2* relaxation times detectable by MRI, as depicted in Figure 1.
This hypothesis was tested in BRAF mutant SKMEL28 human melanoma cells following treatment with the Hsp90 inhibitor
17-AAG and the BRAF inhibitor vemurafenib.
Results
Hsp90 and BRAF inhibitor-induced human melanoma cell differentiation leads to increased pigmentation
Prior to conducting the cell imaging experiments, we first assessed the drug-induced molecular and cellular effects to confirm
the expected phenotypic changes. Treatment of SKMEL28 human melanoma cells with the Hsp90 inhibitor 17-AAG (50 nM)
or the BRAF inhibitor vemurafenib (1 µM) for 72 h led to a reduction in cell counts to 37%±6% and 47%±4% of controls,
respectively (p<0.001).
As shown in Figure 2A, light microscopy revealed stark changes in cell morphology following exposure to the Hsp90 and
BRAF inhibitors, with the adoption of a dendritic appearance characteristic of melanoma cell re-differentiation33. Western blot
analysis of cellular proteins showed reduced ERK phosphorylation following vemurafenib and 17-AAG treatment together with
an increase in Hsp70 in 17-AAG-treated cells, consistent with the expected molecular effects of Hsp90 and BRAF-MEK-ERK
signaling inhibition34, 35. These drug-induced effects were paralleled with induction of tyrosine and gp100 protein expression
under both treatments, confirming induction of melanoma cell re-differentiation (Figure 2B). Inspection of the colour of cell
pellets (containing the same number of cells each) indicated that drug treatment with either 17-AAG or vemurafenib led to
increased cell pigmentation (browner colour) consistent with increased melanin content (Figure 2C). Further, measurement
of intracellular melanin content revealed increased levels in both 17-AAG and vemurafenib-treated SKMEL28 cells up to
2-fold relative to controls (Figure 2D). Thus, at the concentration and exposure time used in our experiments, treatment with
the Hsp90 inhibitor 17-AAG and the BRAF inhibitor vemurafenib led to induction of melanoma cell re-differentiation and
increased cellular melanin levels.
Human melanoma cell re-differentiation is associated with increased PAI signal
Next, we used PAI to assess the optical absorbance properties of control and re-differentiated SKMEL28 human melanoma cells.
The photoacoustic signals of treated and control SKMEL28 cell pellet inclusions, embedded in an agar phantom, were measured
for wavelengths ranging from 670 nm – 900 nm. Figure 3A depicts a photoacoustic image of a representative phantom imaged
at 670 nm, showing inclusions containing control cells, and cells treated with 17-AAG and vemurafenib. Since, the treated cells
express greater levels of melanin compared to controls, consequent generation of PA contrast was expected. Accordingly, an
extremely weak signal was observed from the inclusion of control cells, in contrast to the treated cell inclusions, which were
visible in both 17-AAG- and vemurafenib-exposed cells.
Figure 3B shows a plot of measured PA signal to background ratio (SBR) with respect to wavelength (i.e. a relative
absorbance spectrum) for each inclusion. The SBR spectrum for the treated cell inclusions corresponds to the established
absorption signature of melanin36, confirming an increased level of cellular melanin in response to treatment. Treatment with
vemurafenib and 17-AAG caused an approximately two-fold increase in the SBR at 670 nm (Figure 3C, p = 0.036 and p =
0.0057, respectively) and an approximately 1.3 fold increase in the area under the curve of SBR spectra (Figure 3D, p = 0.0017
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and p = 0.0063, respectively), in comparison to the untreated cells. The degree of increase in treated cell optical absorbance
was similar for both drugs, consistent with the similar levels of increase in intracellular melanin induced post-treatment.
Induction of human melanoma cell pigmentation is associated with shortening of MRI relaxation times T1
and T2*
Melanin is a scavenger of iron, thus increased cell pigmentation is expected to lead to increased iron chelation leading to a
shortening of the MRI relaxation times T1, T2 and T2*. To assess the ability of MRI to detect such effects, we monitored MRI
image contrast obtained from cells grown in standard media as well as media supplemented with exogenous superparamagnetic
iron oxide particles. Representative T1 maps are displayed in Figure 4A, showing differences in contrast between control and
treated cells, which was more pronounced in cells exposed to exogenous iron oxide particles.
Imaging data processing indicated that drug treatment of cells grown in standard media had no significant effect on
longitudinal relaxation time T1 but induced lower transverse relaxation time T2* values, relative to controls (which also
incorporates local susceptibility effects, in this case iron binding-induced field inhomogeneity), in 17-AAG-treated cells.
In contrast, vemurafenib-treated cells showed a significantly lower T1 and T2*, relative to controls (Figure 4A and 4C).
Supplementation of growth media with exogenous iron oxide enhanced the image contrast between control and treated cells and
led to a significant shortening of the MRI relaxation times T1 and T2* in both 17-AAG- and vemurafenib-treated cells (Figure
4B, 4D). Thus, increased cell pigmentation following BRAF or Hsp90 inhibitor treatment leads to increased iron chelation,
resulting in shortening of T1 and T2* MRI relaxation times that is enhanced with exogenous iron supplementation.
As a preliminary indication of the relative sensitivity of PAI and MRI to the changes induced in the melanin content of
the cells, we estimated the coeffiecient of variation (CV) values of the ratio of imaging signal in the treated cells to that in the
controls. The CV values for PAI were 0.186 for treatment with vemurafenib and 0.141 for treatment with 17-AAG, whereas the
same values for MRI T2* (the best performing relaxation time) were 0.186 and 0.419, respectively.
Discussion
Molecular targeted approaches to the treatment of malignant melanoma have in recent years seen unprecedented advances, with
drugs targeting BRAF-MEK-ERK signaling now in routine clinical use, including the BRAF inhibitor vemurafenib37 and many
more undergoing clinical development.
Developing biomarkers of drug activity is crucial for probing target modulation and treatment efficacy and hence clinical
follow up17, 18, with minimally invasive biomarkers of treatment response providing obvious advantages20. In this study, we
set out to investigate the feasibility of using two imaging approaches in monitoring the downstream cellular consequences of
treatment with BRAF and Hsp90 inhibitors in BRAF mutant human melanoma cells. Specifically, we explored the role of
non-invasive imaging with PAI and MRI in detecting melanoma cell functional differentiation following treatment with the
prototype Hsp90 inhibitor 17-AAG and the clinically relevant BRAF inhibitor vemurafenib. These agents cause decreased
MEK-ERK1/2 signaling, inhibition of cell proliferation and induction of human melanoma cell differentiation characterised by
increased cell pigmentation through induction of melanin synthesis and deposition enzymes such as tyrosinase38, 39. Thus we
hypothesised that PAI and MRI may be amenable to the detection of such effects through melanin-generated imaging contrast.
Our findings show that inhibition of Hsp90 and BRAF signaling in human melanoma cells is, as expected, associated
with induction of cell differentiation that leads to increased cell pigmentation characterised by increased tyrosinase protein
expression and melanin content. Importantly, we show that these changes are detectable by non-invasive cell imaging data,
translating to significantly increased PAI signals and significant shortening of the MRI relaxation time T2*, relative to controls.
Calculations of CV show that PAI and MRI were of roughly equal sensitivity in detecting melanin expression due to treatment
with vemurafenib but that PAI may have been more sensitive than MRI in detecting changed expression due to treatment
with 17-AAG. This suggests that PAI might have equivalent or better sensitivity compared to MRI at 7T, and might be more
advantageous compared to MRI at clinical field strengths. However, further work is needed to carry out a thorough sensitivity
comparison of the two methods.
Whilst our data demonstrate the potential of PAI and MRI in detecting melanoma cell re-differentiation post Hsp90 and
BRAF inhibition, each modality has its own merits and demerits for clinical use. MRI is a well-established imaging modality,
routinely used in clinical practice. It is capable of producing detailed images of the anatomical structure of all parts of the body,
but the financial cost of these images is high. PAI, on the other hand, is a relatively new imaging modality that holds great
promise of clinical translation. The main limitation of PAI is its limited imaging depth of up to 5-6 cm40. However, PAI offers
examination convenience as well as reduced cost, and the ability to easily integrate the result in a multivariate approach with
other ultrasound modalities. Several clinical PAI systems existing in a research context have demonstrated the potential of PAI
in imaging cutaneous41, 42 and ocular melanoma43. Stoffels et al.44 demonstrated the clinical potential of PAI in determining
the metastatic status of sentinel lymph nodes in melanoma,located up to a depth of 5 cm, utilising a commercially available
MSOT system. Our results suggest that PAI could potentially visualise the downstream cellular changes, post treatment, in
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such locations (cutaneous, mucosal and ocular melanoma, and metastatic melanoma in lymph nodes and subcutaneous tissues).
Given that both the imaging modalities have their own advantages and limitations, and can provide a range of complementary
information, some similar (for example haemoglobin content and blood oxygenation) and some unique (for example, MRI
apparent diffusion coefficient values related to tissue cell density), a carefully planned imaging approach dependent on the
nature, location and spread of the disease, should permit the selection of either one or both modalities to image the changes in
melanoma cell re-differentiation following BRAF or Hsp90 inhibition.
However, implementation of this approach for in vivo imaging would be accompanied with additional challenges. The
presence of other tissue components, primarily haemoglobin, could introduce complexities in detecting the increased expression
of melanin using PAI and MRI. The paramagnetic nature and absorption of light by oxy- and deoxy-haemoglobin would
necessitate the implementation of approaches to enable differentiation of the MRI and PAI signals of melanin from oxy- and
deoxy-haemoglobin. For PAI, this complexity could be addressed by using spectral unmixing algorithms that could differentiate
and detect the unique optical absorption signatures of melanin, oxy- and deoxy-haemoglobin45, 46. An approach for accounting
for the depth and wavelength-dependence of attenuation of light in tissue47, and heterogenous acoustic properties of tissues48,
might be essential for accurate quantification of an increase in melanin expression, post-treatment. For MRI, deoxygenated
blood generates a very similar contrast to melanin. However, the distribution of oxy- and deoxy- haemoglobin could be imaged
and distinguished from melanin using intrinsic susceptibility MRI with hyperoxia49 as unlike haemoglobin, melanin would not
be sensitive to changes in blood oxygenation. The changes observed by MRI were enhanced with the addition of exogenous
iron, consistent with the mechanism underlying the image contrast. However, under baseline conditions, changes in image
contrast could also be observed between control and treated cells indicating the potential to detect these differences in tumours
based on endogenous contrast. This is also the case for the imaging contrast differences observed with PAI, further emphasising
the value of the approach used here.
Upregulation of melanoma differentiation markers is observed in patients’ tumours following treatment with vemurafenib,
and was associated with disease evolution, being downregulated upon progression. Thus, our findings could have significance
not only for monitoring drug-induced pathway modulation but also for assessing tumour responsiveness to therapy. More
importantly, and of particular relevance to current developments in melanoma, drug-induced upregulation of melanocyte
differentiation antigens facilitates immune recognition of melanoma cells and correlates with increased tumour infiltration by
CD8+ cytotoxic T lymphocytes50. Similar effects have also been described with Hsp90 inhibitors in pre-clinical models51.
Thus, an imaging assay such as the one proposed here should enable stratification of patients who are more likely to benefit
from combination treatment with BRAF-MEK-ERK inhibitors plus immunotherapy, currently under evaluation in several
clinical trials52.
Further work will be required to assess the potential of PAI and MRI in detecting melanoma tumour differentiation in
additional melanoma tumour models with different levels of baseline pigmentation, and assessing the feasibility of our approach
in vivo. Nevertheless, this study provides proof-of-concept for the further study of these biomarkers as non-invasive imaging
tools to report on the downstream cellular consequences of Hsp90 and BRAF-MEK-targeted therapies in melanoma models in
vivo with potential significance for patient follow up and management.
Methods
Cell culture
Human malignant melanoma SKMEL28 cells (harbouring mutant BRAFV 600E ) were originally purchased from the American
Type Culture Collection and authenticated with STR profiling in-house on 16th October 2015. Cells were cultivated in DMEM
containing 10% (v/v) heat inactivated fetal calf serum, 100 U/ml penicillin and 100 g/ml streptomycin (Life Technologies;
Paisley, UK), passaged for no longer than 3 months at a time and regularly screened for mycoplasma.
Cell preparation for imaging analyses
Logarithmically growing SKMEL28 were treated with 50 nM 17-AAG or 1 µM vemurafenib for 72 h to achieve induction
of cell differentiation and a ca. 50% reduction in cell counts. Control cells in all experiments were exposed to DMSO at a
concentration of 0.01%. For PAI, cells were embedded in a cylindrical, tissue mimicking agarose gel phantom of approximately
25 mm diameter and 60 mm height. An open ended syringe (50 ml in volume, 26 mm inner diameter) was filled up with 15 ml
of agar solution, composed of agar (Sigma, 1.5% by weight) and 0.5% Intralipid R© for ultrasonic scattering. The solution was
allowed to solidify at room temperature and three cylindrical wells of approximately 2 mm in diameter and depth were created
on the surface of the base using an indenter. The wells were positioned on the outer edge of the phantom and separated by a gap
of ≈10 mm to avoid any overlap of signals. Cell pellets of the treated and untreated cells were homogenously dispersed in 20
µL low gelling temperature agarose (Sigma, 1% w/v in PBS) at 37◦C and placed in the cylindrical wells in the bottom layer of
solidified agar. On solidification of the pellets, 15 ml of agar solution, with the same concentration of agar and intralipid R© as
the bottom layer was used to cover the inclusions. Cells used in the MRI experiments were grown in standard DMEM medium
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or medium containing iron in the form of the superparamagnetic iron oxide contrast agent Endorem (Guerbet, France) at 0.5
µg/ml during the 72 h incubation with DMSO or drugs to increase iron chelation. At the end of each experiment cells were
harvested by trypsinization and washed twice in PBS and a dry pellet of ≈6 million cells transferred to a 0.75 ml eppendorf
tube for MRI imaging.
PAI data acquisition and processing
Cell pellet-containing phantoms were imaged using the MSOT inVision 256TF system (iThera Medical, Germany). The
phantoms were horizontally positioned in the thin polyethylene membrane holder for MSOT imaging ensuring cell pellets
positioning within the 270◦ angle curvature of the MSOT transducer for homogenous illumination. The holder was submerged
in distilled water at 34◦C and the phantom was positioned in the centre of the MSOT transducer (partial ring array of 256
elements, each with a centre frequency of 5 MHz and a bandwidth of greater than 60%) and imaged at wavelengths over a range
of 670 nm to 950 nm, at intervals of 10 nm (10 pulses per wavelength, 10 nanosecond laser pulses, pulse repetition interval of
100 ms). With a maximum energy of the laser being approximately 70 mJ, the resulting surface fluence on the phantom was
calculated to be approximately 14 mJ/cm2. The experimental and instrument settings were held constant so that the signal
strengths of various inclusions, across independent measurements could be compared. The MSOT images were reconstructed
using the interpolated model matrix inversion algorithm53. The mean and standard deviation of the SBR were calculated from
regions of interests enclosing the entire cell-inclusions and background, across the wavelength range, using the MSOT inVision
software 3.8 (iThera Medical, Germany). Statistical significance of any differences in the peak SBR at 670 nm and the area
under the curve of the SBR plot, between the treated and control cells, was determined using Student’s t-test.
MRI data acquisition and processing
Relaxometry studies were performed on a 7T horizontal bore MRI system (Bruker Instruments, Germany) using a 40 mm
circularly polarised, transmit receive volume coil and the cell pellet-containing tubes immersed in a 50 ml water-filled test tube.
Data processing was carried out in Paravision 6.0 (Bruker, Germany). A first set of T2 weighted images were acquired using a
rapid acquisition with refocused echoes (RARE) sequence, with T Ee f f = 36 ms, TR = 4.5 s, RARE factor = 8, 30 contiguous
1-mm thick transverse slices, 1 average, matrix size 128 × 128 over a 3 × 3 cm2 field of view. These images were used for
planning the subsequent measurement, which included optimization of the local field homogeneity using Mapshim algorithm
and the measurement of:
• T2* maps were calculated from a multi-gradient echo (MGE) sequence (8 readout echoes: TR = 200 ms, first TE/∆TE =
3 ms/3 ms, minimum echo spacing 1.82 ms, flip angle 60◦, 5 slices, slice thickness 1 mm, 8 averages, 128 × 128 scan
matrix, 3 × 3 cm2 field of view).
• T1/T2 relaxation curves were calculated from a rapid inversion recovery (IR) True Fast Imaging with Steady-state
Precession (TrueFISP) sequence (TE = 1.9 ms, TR = 3.8 ms, 50 inversion times spaced 61.16 ms apart, initial inversion
time 25 ms, total scan repetition time of 10s, flip angle 60◦, one 0.5 mm slice, 8 averages of a matrix size of 128 × 128
over a 3 × 3 cm2 field of view).
• T1, T2 and T2* maps were calculated from regions of interest using the in-built post-acquisition Image Sequence Analysis
(ISA) tool. The mean and standard deviation of the ratio of the measured relaxation times of the treated cells to that in
the controls was calculated and plotted using PrismTM version 7 (GraphPad, San Diego).
For display purposes T1 colour coded maps were generated using ImageView Software v5.1.2 (IDL, ITT, US).
The CV of the ratio of imaging signal in the treated cells to that in the controls, was estimated, to acquire an indication of
the relative sensitivity of the two techniques. The CV was calculated as the ratio of the standard deviation to the mean.
Western blotting
Changes in protein expression of the melanoma cell differentiation markers tyrosinase and gp100 were assessed with western
blotting using standard conditions. The primary antibodies used were rabbit anti-tyrosinase (Abcam; Cambridge, UK), anti-
gp100 (Abcam; Cambridge, UK), anti-P-ERK1/2, anti-ERK1/2 (Cell signaling Technology; Danvers, MA, USA), and mouse
anti-Hsp70 (Stressgen Bioreargents; Michigan, USA) and anti-β actin (Chemicon; Hampshire, UK). The secondary antibodies
used were anti-mouse (Dako A/S, Glostrup, Denmark) and anti-rabbit (GE Healthcare Life Sciences; Buckinghamshire, UK).
Antibody-target protein interactions were visualised by enhanced chemiluminescence (GE Healthcare Life Sciences).
Melanin quantification
Melanin content was measured following a previously published protocol54. Briefly, after 72 h treatment with 50 nM 17-AAG
or 1 µM vemurafenib, 1 million cells were solubilised in 100 µl of 1 M NaOH and samples incubated at 60◦C for 1 h and
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vortexed to solubilise the melanin. Absorbance at 405 nm was measured and normalised to protein concentration estimated in
the same sample using the Bradford method.
Statistical Analysis
The statistical significance of the results was assessed using Student’s unpaired 2-tailed t-test with p values≤ 0.05 considered to
be significant. Data are represented as the mean ± standard error of the mean.
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Figure 1. Schematic representation of the molecular basis for the induction in melanin and generation of MRI and PAI-based
contrast following exposure of BRAF mutant human melanoma cells to BRAF and Hsp90 inhibitors.
Figure 2. Hsp90 and BRAF inhibition leads to human melanoma cell differentiation and induction of melanin
synthesis.A) Bright field images showing the increased dendritic morphology in SKMEL28 melanoma cells following
inhibition with vemurafenib (1 µM) or 17-AAG (50 nM) for 72 h (scale bar: 100 µm). B) Western blots confirm the induction
of melanoma cell differentiation (increased gp100) and melanogenesis (increased tyrosinase) concomitant with the expected
molecular signature of BRAF and Hsp90 inhibition following exposure to vemurafenib (Vem) and 17-AAG for 72 h. C) Images
of SKMEL28 pellets showing increased pigmentation following exposure to vemurafenib or 17-AAG for 72 h. The different
tubes contain the same number of cells. D) Spectrophotometric absorbance measurements in SKMEL28 cells confirm
induction of melanin synthesis following treatment with the BRAF inhibitor vemurafenib and the Hsp90 inhibitor17-AAG.
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Figure 3. Changes in PAI signals following melanoma cell differentiation.A) Optoacoustic image of a phantom with the
control and treated cell inclusions at 670 nm absorption. Circular inclusions containing control cells, and cells treated with
17-AAG and vemurafenib to the right, bottom and left of the phantom, respectively (scalebar: 10 mm). B) Signal to
background ratio plot of the untreated cells (•) and cells treated with 17-AAG () and vemurafenib (N), obtained by measuring
the ratio of mean PA signal intensities of the inclusions to the background, at a wavelength interval of 10 nm from 670 nm –
900 nm. The error bars represent standard error of mean (n=3). C) Bar chart comparing the signal to background ratio at 670
nm, between control and treated cells. D) Comparison of area under the curve of the SBR plots between the treated and control
cells. The asterisk sign indicates the significant difference between the mean of the groups (*p<0.05, **p<0.01)
Figure 4. MRI relaxation time changes associated with melanin accumulation under BRAF and Hsp90 inhibition.
(A) and (B) show T1 maps obtained from 4 eppendorf tubes containing water as an external control and 3 different SKMEL28
cell pellets: DMSO treated cells (Cont), cells under Hsp90 inhibition (17-AAG) and cells under BRAF inhibition (Vem). Cells
were cultured in standard medium (A) or medium containing exogenous iron oxide (Endorem, 0.5 µg/ml) (B), which enhanced
differences in T1 between treated and control pellets as shown in the maps. (C) and (D) show the changes in T1, T2 and T2*
relaxation times of treated cells with respect to control, cultured in standard medium (C) and medium containing Endorem (D).
Both drug treatments induce a significant shortening in T1 and T2* values, which is enhanced in cells cultured with Endorem.
The error bars represent standard error of the mean (n=5). (*p<0.05, **p<0.01, ***p<0.001)
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